findmyKOL
Clinical trialNCT03075553TerminatedPhase 2Interventional

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

SponsorMayo ClinicEnrollment12Blastic Plasmacytoid Dendritic Cell NeoplasmHTLV-1 InfectionHepatosplenic T-Cell LymphomaNK-Cell Lymphoma, UnclassifiablePrimary Systemic Anaplastic Large Cell Lymphoma, ALK-NegativeRecurrent Adult T-Cell Leukemia/Lymphoma+11 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Mayo Clinic

    Rochester, Minnesota, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Nivolumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
17 May 2017
Primary completion
29 May 2019
Completion
29 May 2019
Last update posted
21 Apr 2020
Registered enrollment
12
Registry id
NCT03075553
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.